Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study

Ram Weiss, Satish K Garg, Bruce W Bode, Timothy S Bailey, Andrew J Ahmann, Kenneth A Schultz, John B Welsh, John J Shin, Ram Weiss, Satish K Garg, Bruce W Bode, Timothy S Bailey, Andrew J Ahmann, Kenneth A Schultz, John B Welsh, John J Shin

Abstract

Background: ASPIRE In-Home randomized 247 subjects with type 1 diabetes to sensor-augmented pump therapy with or without the Threshold Suspend (TS) feature, which interrupts insulin delivery at a preset sensor glucose value. We studied the effects of TS on nocturnal hypoglycemia (NH) in relation to baseline hemoglobin A1c (A1C) and change in A1C during the study.

Materials and methods: NH event rates and mean area under curve (AUC) of NH events were evaluated at different levels of baseline A1C (<7%, 7-8%, and >8%) and at different levels of changes in A1C (less than -0.3% [decreased], -0.3% to 0.3% [stable], and >0.3% [increased]), in the TS Group compared with the Control Group (sensor-augmented pump only).

Results: In the TS Group, 27.9% of the NH events were accompanied by a confirmatory blood glucose value, compared with 39.3% in the Control Group. Among subjects with baseline A1C levels of <7% or 7-8%, those in the TS Group had significantly lower NH event rates than those in the Control Group (P=0.001 and P=0.004, respectively). Among subjects with decreased or stable A1C levels, those in the TS Group had significantly lower NH event rates, and the events had lower AUCs (P≤0.001 for each). Among subjects with increased A1C levels, those in the TS Group had NH events with significantly lower AUCs (P<0.001).

Conclusions: Use of the TS feature was associated with decreases in the rate and severity (as measured by AUC) of NH events in many subjects, including those with low baseline A1C levels and those whose A1C values decreased during the study period. Use of the TS feature can help protect against hypoglycemia in those wishing to intensify diabetes management to achieve target glucose levels.

Trial registration: ClinicalTrials.gov NCT01497938.

Figures

FIG. 1.
FIG. 1.
(Left panels) Nocturnal hypoglycemia (NH) event rate and (right panels) area under the curve (AUC) of NH events for subjects stratified according to baseline hemoglobin A1c (A1C) (<7%, 7–8%, or >8% in the top, middle, and bottom panels, respectively), changes in A1C (ΔA1C) category (decreased, stable, or increased in the left, middle, and right pairs of columns in each panel), and treatment group assignment (Threshold Suspend [TS] [gray columns] or Control [black columns]). The number of subjects is shown in each column. *P<0.05, **P<0.005 for between-treatment group comparisons.

References

    1. Haugstvedt A, Wentzel-Larsen T, Rokne B, et al. : Perceived family burden and emotional distress: similarities and differences between mothers and fathers of children with type 1 diabetes in a population-based study. Pediatr Diabetes 2011;12:107–114
    1. The Diabetes Control and Complications Trial Research Group: Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991;90:450–459
    1. Diabetes Research in Children Network Study Group: Impaired overnight counterregulatory hormone responses to spontaneous hypoglycemia in children with type 1 diabetes. Pediatr Diabetes 2007;8:199–205
    1. Jauch-Chara K, Hallschmid M, Gais S, et al. : Awakening and counterregulatory response to hypoglycemia during early and late sleep. Diabetes 2007;56:1938–1942
    1. Buckingham B, Wilson DM, Lecher T, et al. : Duration of nocturnal hypoglycemia before seizures. Diabetes Care 2008;31:2110–2112
    1. Desjardins K, Brazeau AS, Strychar I, et al. : Are bedtime nutritional strategies effective in preventing nocturnal hypoglycaemia in patients with type 1 diabetes? Diabetes Obes Metab 2014;16:577–587
    1. Garg S, Brazg RL, Bailey TS, et al. : Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther 2012;14:205–209
    1. Bergenstal RM, Klonoff DC, Garg SK, et al. : Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224–232
    1. Choudhary P, Shin J, Wang Y, et al. : Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011;34:2023–2025
    1. Danne T, Kordonouri O, Holder M, et al. : Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011;13:1129–1134
    1. Ly TT, Nicholas JA, Retterath A, et al. : Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310:1240–1247
    1. Agrawal P, Welsh JB, Kannard B, et al. : Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol 2011;5:1137–1141
    1. Sherr JL, Palau Collazo M, Cengiz E, et al. : Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes even in the absence of low glucose. Diabetes Care 2014;37:773–779
    1. Bailey TS, Weiss R, Bode BW, et al. : Hypoglycemia reduction and changes in A1C in the ASPIRE In-Home Study [abstract 231-OR]. Diabetes 2014;63(Suppl 1):A60
    1. Klonoff DC, Bergenstal RM, Garg SK, et al. : ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. J Diabetes Sci Technol 2013;7:1005–1010
    1. Cryer PE: The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169–3176
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care 2010;33:1004–1008
    1. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271–286
    1. Yeh HC, Brown TT, Maruthur N, et al. : Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 2012;157:336–347
    1. Keenan DB, Mastrototaro JJ, Voskanyan G, et al. : Delays in minimally invasive continuous glucose monitoring devices: a review of current technology. J Diabetes Sci Technol 2009;3:1207–1214

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe